Compare Celsius Holdings, Inc. (CELH) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Celsius Holdings, Inc. vs Cassava Sciences Inc — how do they compare? Celsius Holdings, Inc. trades at $28.03 (market cap $6.89B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Celsius Holdings, Inc. is far larger — about 144.3× Cassava Sciences Inc's market cap. Which is the better fit depends on your goals.
| CELH | FLNA | |
|---|---|---|
Market Cap | $6.89B | $47.75M |
Sector | Consumer Staples | Health |
52-Week High | $64.86 | $4.64 |
52-Week Low | $23.77 | $0.87 |
Enterprise Value | $8.68B | -$34.93M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CELH trades at $27.77, up 16.83% in 24 hours, but technical indicators signal a bearish trend. The company reported Q2 2026 earnings of $0.36 per share, missing estimates, with revenue growth slowing to 11% year-over-year. Recent news includes an analyst downgrade and leadership changes amid an organizational realignment. Valuation metrics remain elevated with a P/E of 120.74 and P/S of 2.37.
The outlook is mixed: strong analyst consensus (95.65% buy ratings) and a $44.08 price target suggest upside, but risks include core brand weakness, margin pressure, and a pending legal investigation. Investors should weigh growth potential from Alani Nu and Rockstar integrations against execution challenges and high valuation multiples.
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Celsius Holdings, Inc.
Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.
Read more on CELH →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
